Development of a Practical Synthesis of the <b>8-FDC</b> Fragment of OPC-167832-Reference-Cited by-同舟云学术

Development of a Practical Synthesis of the 8-FDC Fragment of OPC-167832

Published:2022-02-18 Issue:8 Volume:7 Page:7223-7228
ISSN:2470-1343
Container-title:ACS Omega
language:en
Short-container-title:ACS Omega

Author:

Gopalsamuthiram Vijayagopal¹^ORCID,Ho Dang Binh¹²,Peck Cheryl L.¹,Natarajan Vasudevan¹,Agrawal Toolika¹²,Burns Justina M.¹,Bachert John¹,Cook Daniel W.¹^ORCID,Stringham Rodger W.¹,Nelson Ryan¹,Ahmad Saeed¹,Gupton B. Frank¹^ORCID,Snead David R.¹^ORCID,McQuade D. Tyler¹,Vaidyanathan Rajappa¹^ORCID,Donsbach Kai¹,Sieber Joshua D.¹²^ORCID

Affiliation:

1. Medicines for All Institute, Virginia Commonwealth University School of Engineering, Chemical Development 737 N 5th Street, Richmond, Virginia 23298-0100, United States

2. Department of Chemistry, Virginia Commonwealth University, 1001 West Main Street, Richmond, Virginia 23284-3208, United States

Funder

Bill and Melinda Gates Foundation

Virginia Commonwealth University

Publisher

American Chemical Society (ACS)

Subject

General Chemical Engineering,General Chemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/acsomega.1c06996

Reference11 articles.

1. Comparative Analysis of Pharmacodynamics in the C3HeB/FeJ Mouse Tuberculosis Model for DprE1 Inhibitors TBA-7371, PBTZ169, and OPC-167832

2. National Institute of Allergies and Infectious Diseases. Tuberculosis. https://www.niaid.nih.gov/diseases-conditions/tuberculosis-tb (accessed October 12, 2021).

3. Management of drug-resistant tuberculosis

4. OPC-167832, a Novel Carbostyril Derivative with Potent Antituberculosis Activity as a DprE1 Inhibitor

5. bNakai, Y.; Toda, M.; Eto, R.; Fujii, T. Methods for producing condensed heterocyclic compound and Intermediate of the same. JP 2020079206 A, November 12, 2018.